Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 13Active not recruiting 4Terminated 1Recruiting 1

Sponsor Class

OTHER 10NETWORK 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Breast Neoplasms 19Prostatic Neoplasms 15Multiple Myeloma 15Carcinoma, Non-Small-Cell Lung 12Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 9Leukemia, Myeloid, Acute 7Lung Neoplasms 6Leukemia, Biphenotypic, Acute 6Squamous Cell Carcinoma of Head and Neck 5Neuroblastoma 5Medulloblastoma 5Lymphoma, Mantle-Cell 5Leukemia 5Hodgkin Disease 5Ependymoma 5Colorectal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Burkitt Lymphoma 4Wilms Tumor 3Urinary Bladder Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Oligodendroglioma 3Melanoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

nilotinib 2bosutinib 2Imatinib Mesylate 2Dasatinib 2ruxolitinib 1pembrolizumab 1Tyrosine Kinase Inhibitors 1Specimen Handling 1Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × NETWORK × Leukemia, Myeloid, Chronic-Phase × Clear all
NCT03817398 2026-05-20

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Children's Oncology Group

Phase 2 Active not recruiting
110 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
40 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

SWOG Cancer Research Network

Phase 2 Active not recruiting
81 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT04258943 2025-09-18

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Active not recruiting
60 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡